Evidence map›Paper›PMID 42329236›Full record

ArticleThe Journal of experimental medicine2026

The transcription factor IRF8 drives tumor-specific exhaustion in CD8+ T cells.

Marco Ongaro, Romane Thouenon, Isaac Crespo, Alexandre Dumez, Mélanie Charmoy, Eduardo Roman Camacho, Victoria J Morel, Daniela Cropp, Emma Desponds, Giulio Zanette and 9 more

Abstract read
In one paragraph

Article in The Journal of experimental medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Tumor-driven stabilization of CD8Frontiers in immunology · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Marco OngaroDepartment of Fundamental Oncology UNIL, University of Lausanne, Lausanne, Switzerland.ORCID 0009-0009-2474-8607
Romane ThouenonDepartment of Fundamental Oncology UNIL, University of Lausanne, Lausanne, Switzerland.ORCID 0000-0003-4602-5388
Isaac CrespoDepartment of Fundamental Oncology UNIL, University of Lausanne, Lausanne, Switzerland.ORCID 0000-0003-3151-3901
Alexandre DumezDepartment of Fundamental Oncology UNIL, University of Lausanne, Lausanne, Switzerland.ORCID 0000-0002-7123-4336
Mélanie CharmoyDepartment of Fundamental Oncology UNIL, University of Lausanne, Lausanne, Switzerland.ORCID 0000-0002-2028-1327
Eduardo Roman CamachoDepartment of Fundamental Oncology UNIL, University of Lausanne, Lausanne, Switzerland.ORCID 0009-0009-1937-5009
Victoria J MorelDepartment of Fundamental Oncology UNIL, University of Lausanne, Lausanne, Switzerland.ORCID 0000-0002-8823-3823
Daniela CroppDepartment of Fundamental Oncology UNIL, University of Lausanne, Lausanne, Switzerland.ORCID 0000-0002-6125-9775
Emma DespondsDepartment of Fundamental Oncology UNIL, University of Lausanne, Lausanne, Switzerland.ORCID 0009-0009-0098-9190
Giulio ZanetteDepartment of Fundamental Oncology UNIL, University of Lausanne, Lausanne, Switzerland.ORCID 0009-0006-9116-0262
Yi-Chuan WangDepartment of Fundamental Oncology UNIL, University of Lausanne, Lausanne, Switzerland.ORCID 0009-0003-3818-6138
Letizia VergiliDepartment of Fundamental Oncology UNIL, University of Lausanne, Lausanne, Switzerland.ORCID 0009-0002-0507-9611
Laure TilléDepartment of Fundamental Oncology UNIL, University of Lausanne, Lausanne, Switzerland.ORCID 0000-0001-8163-0837
Inés Di RestaDepartment of Fundamental Oncology UNIL, University of Lausanne, Lausanne, Switzerland.ORCID 0009-0001-7649-7573
Marine M LeblondDepartment of Fundamental Oncology UNIL, University of Lausanne, Lausanne, Switzerland.ORCID 0009-0007-6919-2855
Jésus Corria OsorioDepartment of Fundamental Oncology UNIL, University of Lausanne, Lausanne, Switzerland.ORCID 0000-0001-6844-6170
Ping-Chih HoDepartment of Fundamental Oncology UNIL, University of Lausanne, Lausanne, Switzerland.ORCID 0000-0003-3078-3774
Werner HeldDepartment of Fundamental Oncology UNIL, University of Lausanne, Lausanne, Switzerland.ORCID 0000-0003-3292-1536
Grégory VerdeilDepartment of Fundamental Oncology UNIL, University of Lausanne, Lausanne, Switzerland.ORCID 0000-0001-9445-8474

Funding

ISREC InstituteMax Cloëtta FoundationSwiss Cancer Research Foundation KFS-5386-08-2021Swiss Cancer Research Foundation KFS-5770-02-2023Swiss National Science Foundation 310030_182680Swiss National Science Foundation 310030_200898University of Lausanne
6 · The paper itself

Abstract

T cell exhaustion is a major obstacle to effective immunotherapy in cancer and chronic infection. Here, we identify the transcription factor IRF8 as a tumor-specific regulator of CD8+ T cell exhaustion. IRF8 is strongly expressed in tumor-reactive CD8+ T cells but not during chronic viral infection. Its expression is induced by TCR signaling and can be suppressed by type I IFN (IFN-I). Sustained IFN-I signaling, a hallmark of chronic infection, correlates with reduced chromatin accessibility at the Irf8 locus and progressive repression of Irf8 expression. In tumor-specific CD8+ T cells, IRF8 overexpression enhanced TOX expression while reducing IFNγ, granzyme B, and TNF production. Conversely, Irf8 deficiency diminished exhaustion, restored effector functions, and improved tumor control. Mechanistically, IRF8 directly binds the Tox locus and promotes its transcription. We further show that additional IRF-family transcription factors contribute similarly to the exhausted T cell program, identifying this transcriptional network as a key regulator of tumor-associated T cell dysfunction.

Indexed as

CD8-Positive T-LymphocytesInterferon Regulatory FactorsAnimalsHigh Mobility Group ProteinsHumansInterferon Regulatory Factor-8Interferon Type IMiceMice, Inbred C57BLSignal TransductionT-Cell ExhaustionHigh Mobility Group ProteinsInterferon Regulatory Factor-8Interferon Regulatory FactorsInterferon Type ITOX protein, human

Identifiers

PMID42329236
PMCPMC13285691

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.